The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 339:1734-1738 December 10, 1998 Number 24
NextNext

Prenatal Diagnosis of Fetal RhD Status by Molecular Analysis of Maternal Plasma
Y.M. Dennis Lo, M.R.C.P., N. Magnus Hjelm, F.R.C.Path., Carrie Fidler, Ph.D., Ian L. Sargent, Ph.D., Michael F. Murphy, F.R.C.Path., Paul F. Chamberlain, M.D., Priscilla M.K. Poon, Ph.D., Christopher W.G. Redman, F.R.C.P., and James S. Wainscoat, F.R.C.Path.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Commentary
-Editorial
 by Bowman, J. M.

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background The ability to determine fetal RhD status noninvasively is useful in the treatment of RhD-sensitized pregnant women whose partners are heterozygous for the RhD gene. The recent demonstration of fetal DNA in maternal plasma raises the possibility that fetal RhD genotyping may be possible with the use of maternal plasma.

Methods We studied 57 RhD-negative pregnant women and their singleton fetuses. DNA extracted from maternal plasma was analyzed for the RhD gene with a fluorescence-based polymerase-chain-reaction (PCR) test sensitive enough to detect the RhD gene in a single cell. Fetal RhD status was determined directly by serologic analysis of cord blood or PCR analysis of amniotic fluid.

Results Among the 57 RhD-negative women, 12 were in their first trimester of pregnancy, 30 were in their second trimester, and 15 were in their third trimester. Thirty-nine fetuses were RhD-positive, and 18 were RhD-negative. In the samples obtained from women in their second or third trimester of pregnancy, the results of RhD PCR analysis of maternal plasma DNA were completely concordant with the results of serologic analysis. Among the maternal plasma samples collected in the first trimester, 2 contained no RhD DNA, but the fetuses were RhD-positive; the results in the other 10 samples were concordant (7 were RhD-positive, and 3 RhD-negative).

Conclusions Noninvasive fetal RhD genotyping can be performed rapidly and reliably with the use of maternal plasma beginning in the second trimester of pregnancy.


Source Information

From the Department of Chemical Pathology, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China (Y.M.D.L., N.M.H., P.M.K.P.); and the Department of Hematology (C.F., M.F.M., J.S.W.) and the Nuffield Department of Obstetrics and Gynecology (I.L.S., P.F.C., C.W.G.R.), John Radcliffe Hospital, Oxford, United Kingdom.

Address reprint requests to Dr. Lo at the Department of Chemical Pathology, Rm. 38023, Clinical Sciences Bldg., Prince of Wales Hospital, 30–32 Ngan Shing St., Hong Kong, China.

Full Text of this Article


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.